LinXCell Biotechnologies

LinXCell Biotechnologies is a Chinese preclinical cell therapy company developing oncology and immunology products based on a chemical coupling approach that covalently links antibodies, peptides, and immune cells. The company states that it is building next-generation cell therapies intended to improve efficacy, safety, manufacturability, and cost versus conventional approaches. Its technology stack includes immune-cell expansion, chemical coupling, nanobody/antibody screening, and preclinical development platforms. LinXCell highlights work in γδT and NK cell manufacturing and has disclosed a panel of tumor-related nanobody targets, but it has not publicly provided a detailed named clinical pipeline. The company appears to be private and headquartered in Hefei, China, after relocating from Beijing.